Manimozhiyan Arumugam is a Group Leader and Associate Professor at the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark. He received his PhD in computational biology from the European Molecular Biology Laboratory (Heidelberg) in 2010. He studies the trillions of microbes that inhabit the human gut, collectively called the human gut microbiota. As part of the European MetaHIT consortium, he has contributed to major advances in understanding the human gut microbiome (collective genomes of the human gut microbiota), including the establishment of the first human gut microbial gene catalog and the discovery of enterotypes.
Dr. Arumugam leads the “Microbiome Systems Biology” research group that investigates how our health and diseases are influenced by our gut microbiome. His research is interdisciplinary, combining metagenomics (a technique to study the gut microbiome), genomics, genetics, (meta)transcriptomics, and metabolomics in order to study the host-microbial cross-talk. The group also has international collaborations studying the interaction between the gut microbiome and the host in the context of several other diseases, including cardiometabolic diseases, chronic liver diseases and cancer. He is the principal investigator in several externally funded studies investigating the role of gut microbiome in multiple sclerosis (Lundbeck Foundation), obesity (Novo Nordisk Foundation), alcoholic liver fibrosis (EU Horizon 2020), ageing (Danish Independent Research Council) and producing antimicrobial peptides (Danish Independent Research Council).
Dr. Arumugam has published 36 research articles, 7 of them in Nature (2 as shared first author), 1 in Science and 1 in Cell. He has an h-index of 25 with >10,000 total citations.